REG - Cizzle Biotechnology - Lung Cancer Detection Strategic Alliance in China

Cizzle Biotechnology HoldingsAnnouncement

25/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211125:nRSY5195Ta&default-theme=true

RNS Number : 5195T  Cizzle Biotechnology Holdings PLC  25 November 2021

25 November 2021

Cizzle Biotechnology Holdings Plc

 

("Cizzle Biotechnology" or the "Company")

 

Strategic Alliance for Early Lung Cancer Detection in China

 

Cizzle Biotechnology, the UK based diagnostics developer, is pleased to
announce that it has executed a Memorandum of Understanding ("MOU") with the
International Co-Innovation Centre for Advanced Medical Technology ("iCCAMT")
and Shenzhen Intelliphecy Life Technologies Co., Ltd. ("Intelliphecy") to
develop and market the Company's proprietary early lung cancer diagnostic
tests based on the CIZ1B cancer biomarker in China.

Lung cancer is a major public health problem worldwide and especially in
China, where it is still the most common diagnosed cancer and the leading
cause of cancer related deaths. Early detection is essential in enabling early
therapeutic intervention and improved outcomes.

iCCMAT, founded with German Medical Valley, Robert Bosch GmbH and Sinopharm
Group, aims to accelerate global med-tech innovation in the Chinese market, by
bringing together world leading expertise. The strategic alliance is intended
to accelerate product development and clinical trials to achieve early
adoption within major cancer centers throughout China.

The MOU is non-binding, but it is intended that a full commercial contract
will be entered into in due course whereby the parties will collaborate
closely in end-to-end development, manufacture and sale of early cancer
detection products and services. The MOU envisages that iCCAMT and
Intelliphecy will fund the activities in China and Cizzle Biotechnology will
receive payment for monoclonal antibodies and reagents produced, and services
provided, together with royalties on any sales of products and services in
China.

Initial pilots of Cizzle Biotechnology's lung cancer diagnostic tests are
planned at the Cancer Hospital Chinese Academy of Medical Sciences, National
Cancer Centre and Beijing Cancer Hospital affiliated with Peking University.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

"We are delighted to establish this important collaboration to bring our
simple blood test for the early detection of
lung cancer based on the C1Z1B biomarker to China. In 2020, nearly
715,000 deaths were caused by lung cancer in China, accounting for around 24
percent of all the three million cancer deaths* there. It is a major health
and economic challenge and together with our new partners we aim to contribute
to building effective strategies for decreasing the cancer burden in China as
part of their comprehensive prevention and control measures."

Commenting, Dr Hui Wu, CEO and Founder of iCCAMT said:

"The C1Z1B biomarker developed by Cizzle Biotechnology has shown promising
results for lung cancer early detection in the UK. To help the Chinese
population access cost-efficient lung cancer detection, the iCCAMT would
foster this technology implementation in China with support from its
nationwide network of national clinical centers and key opinion
leaders."

Commenting, Dr Xiaoyun Huang, CEO and Founder of Intelliphecy said:

"The ability to detect lung cancer at an early stage is key for the
improvement of patient survival and can eventually reduce the medical burden
of lung cancer. We are excited to enter into partnership with Cizzle
Biotechnology and iCCAMT to develop an early lung cancer diagnostic test based
on Cizzle's proprietary technology with the CIZ1B cancer biomarker. We are
looking forward to reaching important milestones together with our partners in
the near future."

 

*https://www.statista.com/statistics/1053667/china-cancer-death-number-by-type/

 

This announcement contains inside information for the purposes of article 7 of
EU Regulation 596/2014 which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018 ("UK MAR").  Upon the publication of
this announcement this inside information is now considered to be within the
public domain.

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 33285656
 John Depasquale
 Alex Brearley

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

Notes to Editors:

 

About Cizzle Biotechnology

 

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer.  Cizzle Biotechnology is a spin- out from the University of
York, founded in 2006 around the work of Professor Coverley and colleagues.
Its proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early stage lung cancer.

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

 

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

About International Co-Innovation Centre for Advanced Medical Technology
("iCCAMT")

 

iCCAMT, founded with German Medical Valley, Robert Bosch GmbH, Sinopharm
Group, aims to accelerate global healthcare innovation in China. iCCAMT is
dedicated to support innovative healthcare SMEs (small and medium sized
companies) to grow in China and promote technology transfer. With global
health technology network and supports from industry giants, iCCAMT has
developed comprehensive platforms to strengthen cross-border health technology
collaborations, and help global health technology companies enter the China
market.

 

For more information, please see http://www.iccamt.com (http://www.iccamt.com)
 

 

About Shenzhen Intelliphecy Life Technologies Co., Ltd. ("Intelliphecy")

 

Intelliphecy is aiming to innovate technologies in the hope to win the war
against cancer, aspiring to out-smart cancer cells with an intelligent
prophecy. At the core of Intelliphecy's technology portfolio lies artificial
intelligence driven big data analytics, which is devoted to predictive
modeling of cancer hallmarks using quantitative information. Its research and
development is grounded in both identification of cancer at early stage and
prediction of optimal treatment strategies for individual cancer patients.
Intelliphecy has established research collaborations with major cancer centres
throughout China.

For more information, please see http://www.intelliphecy.com
(http://www.intelliphecy.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALLEAPFLALAFFFA